JAK
Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.
- A4510 1,2,3,4,5,6-HexabromocyclohexaneSummary: JAK2 tyrosine kinase inhibitor
- A4511 CercosporamideTarget: JAK|MNKSummary: Mnk2 and JAK3 inhibitor
- A4512 Cucurbitacin ITarget: STAT|JAKSummary: STAT3/JAK2 signaling inhibitor
- A4513 Lestaurtinib1 CitationSummary: JAK2/FLT3/TrkA inhibitor
- A4515 SD 1008Summary: Inhibitor of JAK2/STAT3 signaling pathway,apoptosis inducer
- A4516 TCS 21311Summary: JAK3 inhibitor
- A4517 ZM 449829Summary: JAK3 inhibitor
- A4514 NSC 33994Summary: Selective JAK2 inhibitor
- B8023 Cerdulatinib (PRT062070)Target: JAK|Syk|TYK2Summary: Syk/JAK inhibitor
- B5929 Decernotinib(VX-509)Summary: Selective and orally active JAK3 inhibitor